Abbvie-Header Abbvie-Header

X

Find Urology Clinical Drug Pipeline Developments & Deals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vibegron

            Therapeutic Area: Urology Product Name: Gemtesa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 31, 2021

            Details:

            Based on this agreement, Eisai will acquire exclusive development and marketing rights from Kyorin for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mirabegron

            Therapeutic Area: Urology Product Name: Myrbetriq

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 26, 2021

            Details:

            The U.S. Food and Drug Administration (FDA) approved Myrbetriq for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq® Granules for the treatment of NDO in pediatric patients aged three years and older.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vibegron

            Therapeutic Area: Urology Product Name: Gemtesa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 23, 2021

            Details:

            Vibegron is a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mirabegron

            Therapeutic Area: Urology Product Name: Myrbetriq

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2021

            Details:

            The NDA and sNDA were based on findings from a Phase 3 pivotal study that evaluated the efficacy, safety, tolerability and pharmacokinetics of mirabegron in children and adolescents with NDO and using clean intermittent catheterization.